Literature DB >> 31104136

Advanced implantable drug delivery technologies: transforming the clinical landscape of therapeutics for chronic diseases.

Fernanda P Pons-Faudoa1,2, Andrea Ballerini1,3, Jason Sakamoto1, Alessandro Grattoni4,5,6.   

Abstract

Chronic diseases account for the majority of all deaths worldwide, and their prevalence is expected to escalate in the next 10 years. Because chronic disorders require long-term therapy, the healthcare system must address the needs of an increasing number of patients. The use of new drug administration routes, specifically implantable drug delivery devices, has the potential to reduce treatment-monitoring clinical visits and follow-ups with healthcare providers. Also, implantable drug delivery devices can be designed to maintain drug concentrations in the therapeutic window to achieve controlled, continuous release of therapeutics over extended periods, eliminating the risk of patient non-compliance to oral treatment. A higher local drug concentration can be achieved if the device is implanted in the affected tissue, reducing systemic adverse side effects and decreasing the challenges and discomfort of parenteral treatment. Although implantable drug delivery devices have existed for some time, interest in their therapeutic potential is growing, with a global market expected to reach over $12 billion USD by 2018. This review discusses implantable drug delivery technologies in an advanced stage of development or in clinical use and focuses on the state-of-the-art of reservoir-based implants including pumps, electromechanical systems, and polymers, sites of implantation and side effects, and deployment in developing countries.

Entities:  

Keywords:  Implants; Long-acting formulations; MEMS; NEMS; Non-biodegradable polymers

Mesh:

Substances:

Year:  2019        PMID: 31104136     DOI: 10.1007/s10544-019-0389-6

Source DB:  PubMed          Journal:  Biomed Microdevices        ISSN: 1387-2176            Impact factor:   2.838


  24 in total

1.  Trans-urocanic acid enhances tenofovir alafenamide stability for long-acting HIV applications.

Authors:  Antons Sizovs; Fernanda P Pons-Faudoa; Gulsah Malgir; Kathryn A Shelton; Lane R Bushman; Corrine Ying Xuan Chua; Peter L Anderson; Pramod N Nehete; K Jagannadha Sastry; Alessandro Grattoni
Journal:  Int J Pharm       Date:  2020-07-11       Impact factor: 5.875

Review 2.  Emerging biomaterial-based strategies for personalized therapeutic in situ cancer vaccines.

Authors:  Dixita Ishani Viswanath; Hsuan-Chen Liu; David P Huston; Corrine Ying Xuan Chua; Alessandro Grattoni
Journal:  Biomaterials       Date:  2021-11-30       Impact factor: 12.479

3.  3D-printed implantable devices with biodegradable rate-controlling membrane for sustained delivery of hydrophobic drugs.

Authors:  Camila J Picco; Juan Domínguez-Robles; Emilia Utomo; Alejandro J Paredes; Fabiana Volpe-Zanutto; Dessislava Malinova; Ryan F Donnelly; Eneko Larrañeta
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.419

Review 4.  Recent Progress in Materials Chemistry to Advance Flexible Bioelectronics in Medicine.

Authors:  Gaurav Balakrishnan; Jiwoo Song; Chenchen Mou; Christopher J Bettinger
Journal:  Adv Mater       Date:  2022-01-27       Impact factor: 30.849

5.  Extending drug release from implants via transcutaneous refilling with solid therapeutics.

Authors:  Nicola Di Trani; Fernanda P Pons-Faudoa; Antons Sizovs; Kathryn A Shelton; Mark A Marzinke; Pramod N Nehete; Alessandro Grattoni
Journal:  Adv Ther (Weinh)       Date:  2021-12-26

6.  Digital droplet infusion.

Authors:  Zecong Fang; Andrew I Li; Hong Liu; Tingrui Pan
Journal:  Lab Chip       Date:  2020-11-13       Impact factor: 6.799

Review 7.  Long-acting approaches for delivery of antiretroviral drugs for prevention and treatment of HIV: a review of recent research.

Authors:  Denise A Cobb; Nathan A Smith; Benson J Edagwa; JoEllyn M McMillan
Journal:  Expert Opin Drug Deliv       Date:  2020-07-06       Impact factor: 6.648

8.  Preventive efficacy of a tenofovir alafenamide fumarate nanofluidic implant in SHIV-challenged nonhuman primates.

Authors:  Fernanda P Pons-Faudoa; Antons Sizovs; Kathryn A Shelton; Zoha Momin; Jean A Niles; Lane R Bushman; Jiaqiong Xu; Corrine Ying Xuan Chua; Joan E Nichols; Sandra Demaria; Michael M Ittmann; Trevor Hawkins; James F Rooney; Mark A Marzinke; Jason T Kimata; Peter L Anderson; Pramod N Nehete; Roberto C Arduino; Mauro Ferrari; K Jagannadha Sastry; Alessandro Grattoni
Journal:  Adv Ther (Weinh)       Date:  2020-12-16

Review 9.  Tenofovir Alafenamide for HIV Prevention: Review of the Proceedings from the Gates Foundation Long-Acting TAF Product Development Meeting.

Authors:  Joseph W Romano; Marc M Baum; Zach R Demkovich; Frank Diana; Charles Dobard; Paul L Feldman; J Gerardo Garcia-Lerma; Alessandro Grattoni; Manjula Gunawardana; Duy-Khiet Ho; Thomas J Hope; Ivana Massud; Mark Milad; John A Moss; Fernanda P Pons-Faudoa; Shane Roller; Ariane van der Straten; Selvi Srinivasan; Ronald S Veazey; Doris Zane
Journal:  AIDS Res Hum Retroviruses       Date:  2021-06       Impact factor: 2.205

10.  The Translational and Regulatory Development of an Implantable Microdevice for Multiple Drug Sensitivity Measurements in Cancer Patients.

Authors:  Christine Dominas; Sharath Bhagavatula; Elizabeth Stover; Kyle Deans; Cecilia Larocca; Yolanda Colson; Pierpaolo Peruzzi; Adam Kibel; Nobuhiko Hata; Lillian Tsai; Yin Hung; Robert Packard; Oliver Jonas
Journal:  IEEE Trans Biomed Eng       Date:  2021-12-23       Impact factor: 4.538

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.